Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-05-21 Director's Dealing
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
董事增持股份结果公告
Director's Dealing Classification · 100% confidence The document is titled '董事增持股份结果公告' which translates to 'Announcement of Directors' Shareholding Increase Results'. It details the shareholding increase plans and the actual results of share purchases by company directors. The content includes specific share quantities, prices, periods, and confirmations of compliance with regulations. This is a report on insider transactions by directors, not a financial report, earnings release, or general regulatory filing. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on share transactions by directors, confirming the classification.
2024-05-21 Chinese
关于收到北京证券交易所对公司年报问询函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Inner Mongolia Datang Pharmaceutical Co., Ltd. regarding the receipt of an inquiry letter from the Beijing Stock Exchange about the company's 2023 annual report. The text includes detailed questions from the exchange about various financial and operational aspects of the company, such as revenue, costs, fixed assets, inventory, and accounts receivable, and requests written responses by a certain date. The document does not contain the annual report itself or detailed financial statements but is a regulatory communication about the annual report review process. The document length is under 5,000 characters and it states that the company will respond and disclose further information later. This fits the pattern of a Regulatory Filing (RNS) rather than the Annual Report (10-K) or an Audit Report (AR).
2024-05-16 Chinese
高级管理人员辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel, specifically the financial director Zhao Ming, including details about the resignation date, shareholding, and impact on the company. It does not contain financial statements, audit information, or regulatory certifications. The content focuses on management changes rather than financial results or governance rules. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2024-04-29 Chinese
高级管理人员任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel, specifically the financial officer of the company. It details the nomination, approval votes, background of the appointee, and compliance with relevant laws and company rules. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of management changes rather than financial reports or other filings.
2024-04-29 Chinese
第三届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 16th meeting of the 3rd Board of Directors of Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of the appointment of a new financial officer. It references related announcements but does not contain financial statements or detailed management reports. The content focuses on board decisions and management appointments, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a regulatory filing of financial data, but a formal announcement of board resolutions.
2024-04-29 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "内蒙古大唐药业股份有限公司 2024 年第一季度报告" which translates to "Inner Mongolia Datang Pharmaceutical Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period January to March 2024. It is unaudited as noted in the text. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.